Skip to main content
6487 search results for:

Myasthenia Gravis 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2024 | Myasthenia Gravis | OriginalPaper

    Taste disorders and alopecia in myasthenia gravis

    Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness with fatigue and mediated by autoantibodies against acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) [ 1 ]. Non-motor symptoms, such as pure red …

  2. Open Access 22-04-2024 | Myasthenia Gravis | Online First

    Recommendations for the management of myasthenia gravis in Belgium

    International guidelines on the treatment of myasthenia gravis (MG) have been published but are not tailored to the Belgian situation. This publication presents recommendations from a group of Belgian MG experts for the practical management of MG …

  3. Open Access 24-02-2024 | Fatigue | OriginalPaper

    Improvement of fatigue in generalised myasthenia gravis with zilucoplan

    Myasthenia gravis (MG) is a debilitating autoimmune neuromuscular disease characterised by fluctuating muscle weakness with a prevalence of 100–350 people per million globally [ 1 , 2 ]. MG causes neuromuscular or muscle fatiguability, where …

  4. Open Access 27-04-2024 | Myasthenia Gravis | Online First

    Epidemiology, Patient Characteristics, and Treatment Patterns of Myasthenia Gravis in Taiwan: A Population-Based Study

    Myasthenia gravis (MG) is a chronic disease mediated by autoantibodies to important proteins, such as acetylcholine receptors and muscle-specific tyrosine kinase in the postsynaptic region of the neuromuscular junction, leading to ocular, bulbar …

  5. 23-04-2024 | Myasthenia Gravis | Online First

    COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China

    Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of coronaviral subfamily [ 1 ]. The COVID-19 pandemic has had a huge impact on global health since it was first reported in …

  6. 23-02-2024 | Myasthenia Gravis | Letter

    Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report

  7. 30-03-2024 | Myasthenia Gravis | Online First

    Detecting muscle-specific kinase myasthenia gravis in atypical presentations

  8. Open Access 20-04-2024 | Myasthenia Gravis | Online First

    Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison

    Generalized myasthenia gravis (gMG) is a rare, chronic, neuromuscular autoimmune disease, mediated by pathogenic immunoglobulin auto-antibodies targeting the neuromuscular junction [ 1 ]. gMG is a debilitating disease that negatively impacts …

  9. 19-03-2024 | Myasthenia Gravis | News | Article

    Sustained efficacy with batoclimab in myasthenia gravis

    The monoclonal antibody batoclimab offers superior sustained improvements in the activities of daily living score versus placebo in patients with myasthenia gravis.

  10. 05-04-2024 | Myasthenia Gravis | Online First

    Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis

    Serological tests are important to detect autoantibodies (autoAbs) in patients with autoimmune neuropathies (AN) and myasthenia gravis (MG) as they are biomarkers for diagnosis, stratification, treatment selection, and monitoring. However, tests …

  11. 03-03-2024 | Myasthenia Gravis | ReviewPaper

    The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis

    Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against acetylcholine receptors (AChR), muscle-specific kinase (MuSK), or low-density lipoprotein receptor-related protein 4 [ 1 , 2 ]. Immunoglobulin G (IgG) binds to AChR, MuSK …

  12. 25-03-2024 | Myasthenia Gravis | Online First

    Real-World experience with efgartigimod in patients with myasthenia gravis

    Recommendations for the treatment of myasthenia gravis (MG) have been difficult to develop because of limited evidence from large randomized controlled trials. New drugs and treatment approaches have recently been shown to be effective in phase 3 …

  13. Open Access 01-12-2024 | Myasthenia Gravis | OriginalPaper

    Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis

    Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction [ 1 ]. The clinical hallmark of MG is muscle weakness associated with fatigability, which can lead to potentially life-threatening exacerbations, such as …

  14. 02-04-2024 | Salbutamol | Online First

    Oral salbutamol for symptomatic treatment in MuSK antibody-positive myasthenia gravis: a single-centre experience

    Symptomatic treatment in muscle-specific kinase antibody positive myasthenia gravis (MuSK MG) can pose a challenge for the clinical neurologist. Animal models have demonstrated that the MuSK antibody results in defects in the function of …

  15. 06-03-2024 | Myasthenia Gravis | News | Article

    Immunosuppressors improve QoL in myasthenia gravis

    The immunosuppressors azathioprine and mycophenolate mofetil significantly improve quality of life, function, and muscle strength in patients with myasthenia gravis, and are relatively safe and inexpensive.

  16. Open Access 01-12-2024 | Myasthenia Gravis | OriginalPaper

    Social support and medication adherence among adult myasthenia gravis patients in China: the mediating role of mental health and self-efficacy

    Myasthenia gravis (MG) is a rare chronic neuromuscular disorder characterized by progressive physical decline and requires long-term pharmacological treatment. Globally, the incidence of MG is approximately 1.7 to 21.3 per million person-years and …

  17. 11-04-2024 | Myasthenia Gravis | Online First

    Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report

  18. 28-02-2024 | Myasthenia Gravis | Online First

    Clinical features of double seronegative ocular myasthenia gravis

    Myasthenia gravis (MG) is not uncommon, with a reported frequency of 23.1 per 100,000 persons in Japan [ 1 ]. Most patients present with ocular symptoms during the course of MG, with about 70% presenting with ptosis and 50% with diplopia as the …

  19. 05-12-2023 | Myasthenia Gravis | OriginalPaper

    Unique association of anti-GABAA receptor encephalitis and myasthenia gravis in a patient with type A thymoma

    Association between anti-GABAAR encephalitis and myasthenia gravis is extremely rare with few reported cases. Herein, we report a case of a female patient diagnosed with anti-GABAAR encephalitis and thymoma at the first admission. She was …

  20. 23-01-2024 | Myasthenia Gravis | ReviewPaper

    A New Era in the Treatment of Myasthenia Gravis: Six New Medications in The Last 6 Years

    Myasthenia gravis (MG) is a chronic autoimmune neuromuscular junction disorder. International Consensus treatment guidelines were published in 2016 and updated in 2020 [ 1 , 2 …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.